Department of Medical Oncology, Dana Farber Cancer Institute, Boston, Massachusetts.
Search for other works by this author on: ...
Search for other works by this author on: ...
Search for other works by this author on: ...
University of Nebraska Medical Center, Omaha, NE, ...
Department of Hematology and Medical Oncology, Emory University School of Medicine, Atlanta, Georgia.
Adding the PD-1 inhibitor pembrolizumab to chemoradiotherapy for high-risk, locally advanced cervical cancer significantly improves patients’ overall survival compared to treatment with CRT alone.
This open access article is distributed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0) license. This work is licensed under a Creative Commons ...
Copyright held by the owner/author(s).
Program of Immunology and Immunotherapy, Cima Universidad de Navarra, Pamplona, Spain.
According to the phase IIIb/IV DESTINYBreast-12 Trial, the results of which were presented at the European Society for Medical Oncology 2024 Congress in Barcelona, Spain, and concurrently published, ...
Two HER2-targeted tyrosine kinase inhibitors, BAY 29270078 and zongertinib, each showed robust efficacy and safety in early phase. Patients experienced significant tumor shrinkage rates, and the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback